Lopinavir

Overview
Catalog #	bs-75596c-25mg
Product Name	Lopinavir
Specifications
Storage Buffer	Solid
Storage Condition	Stable for 2 years after receipt when stored at -20°C.
Target
Product Information	CAS Number: 192725-17-0 Molecular formula: C37H48N4O5 Molecular weight: 628.8 Purity: >98% (1H-NMR) Appearance: White to off-white solid. Solubility: Soluble in ethanol (20mg/ml), DMSO (15mg/ml) or dimtheylformamide (15mg/ml). InChiKey: KJHKTHWMRKYKJE-SUGCFTRWSA-N SMILES: O=C1NCCCN1[C@@H](C(C)C)C(N[C@@H](CC2=CC=CC=C2)C[C@H](O)[C@H](CC3=CC=CC=C3)NC(COC4=C(C)C=CC=C4C)=O)=O
Description	The antiviral agent Lopinavir is a potent inhibitor of HIV-1 protease (Ki=1.3pM for wild-type enzyme) and has been shown to block the replication of clinical isolates of HIV (EC50s=5-52nM). Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir). Lopinavir/ritonavir inhibits the HIV protease enzyme by forming an inhibitor-enzyme complex thereby preventing cleavage of the gag-pol polyproteins. Immature, non- infectious viral particles are subsequently produced. Lopinavir also has an ability to inhibit ZMPSTE24 (zinc metallopeptidase STE24). HIV-PIs block prelamin A processing by directly affecting the enzymatic activity of ZMPSTE24 and in this way they may contribute to lipodystrophy in individuals undergoing HIV-PI treatment. It also has been shown to inhibit meningioma cell proliferation, induce apoptosis on lymphoma cells and inhibit insulin signaling. Shown in a SARS-CoV-2 protease structure model study to potentially bind and inhibit the coronavirus endopeptidase C30 (CEP_C30) of SARS-CoV-2. A initial randomized trial study was not successful.